1,6-Disubstituted-1H-benzo[d]imidazol-2(3H)-one Derivatives as PIM Kinase Inhibitors
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
PIM proteins, which are proto-oncogenic serine/threonine kinases that are highly expressed in hematological malignancies and solid cancers, are potential molecular targets for anticancer drugs. 1H-Benzo[d]imidazol-2(3H)-one is a key structure in drug discovery, and several of its analogues have been developed as therapeutics. 1,6-Disubstituted-1H- benzo[d]imidazol-2(3H)-one derivatives were synthesized and evaluated in terms of their inhibitory activities against all three PIM kinases. Systematic structural modifications of benzo[d]imidazol-2-one at the 1- and 6-positions led to the discovery of pan-PIM inhibitors represented by 9. The binding modes of the synthesized compounds and the effects of the substituents on the selectivities among the PIM kinase isoforms were studied to confirm 1,6-disubstituted-1H- benzo[d]imidazol-2(3H)-one as a scaffold for use in the discovery of PIM kinase inhibitors.
Abstract
PIM proteins, which are proto-oncogenic serine/threonine kinases that are highly expressed in hematological malignancies and solid cancers, are potential molecular targets for anticancer drugs. 1H-Benzo[d]imidazol-2(3H)-one is a key structure in drug discovery, and several of its analogues have been developed as therapeutics. 1,6-Disubstituted-1H- benzo[d]imidazol-2(3H)-one derivatives were synthesized and evaluated in terms of their inhibitory activities against all three PIM kinases. Systematic structural modifications of benzo[d]imidazol-2-one at the 1- and 6-positions led to the discovery of pan-PIM inhibitors represented by 9. The binding modes of the synthesized compounds and the effects of the substituents on the selectivities among the PIM kinase isoforms were studied to confirm 1,6-disubstituted-1H- benzo[d]imidazol-2(3H)-one as a scaffold for use in the discovery of PIM kinase inhibitors.
참고문헌 (16)
- Mikkers H, "Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors", Mol Cell Biol, 24, pp.6104~6115 (2004)
- Santio NM, "PIM kinases : From survival factors to regulators of cell motility", Int J Biochem Cell Biol, 93, pp.74~85 (2017)
- Amson R, "The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias", Proceedings of the National Academy of Sciences, 86, pp.8857~8861 (1989)
- Gayet J, "In vivo glucose carbon utilization in the cerebral hemispheres, optic lobes and cerebellum of chickens during postnatal development", J Physiol(Paris), 63, pp.218A~ (1971)[DOI]
- Aho TL, "Pim-1 kinase promotes inactivation of the proapoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site", FEBS Lett, 571, pp.43~49 (2004)
- Yan B, "The PIM-2 kinase phosphorylates BAD on serine 112and reverses BAD-induced cell death", J Biol Chem, 278, pp.45358~45367 (2003)
- Popivanova BK, "Proto-oncogene, Pim-3 with serine", threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent Bad-mediated apoptosis, 2007, pp.98, 321~328
- Zhang Y, "Pim kinase-dependent inhibition of c-Myc degradation", Oncogene, 27, pp.4809~4819 (2008)
- Liu B, "Pim-3 promotes human pancreatic cancer growth by regulating tumor vasculogenesis", Oncol Rep, 31, pp.2625~2634 (2014)
- Alnabulsi S, "Pim kinase inhibitors in cancer : medicinal chemistry insights into their activity and selectivity", Drug Discov Today, 25, pp.2062~2069 (2020)
- Qian KC, "Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase", J Biol Chem, 280, pp.6130~6137 (2005)
- imidazol-2(3H)-one Derivatives, "Molecules", 2016, 516~
- Trott O, "AutoDock Vina : improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading", J Comput Chem, 31, pp.455~461 (2010)
- Burger MT, "Structure guided optimization, in vitro activity, and in vivo activity of pan-PIM kinase inhibitors", ACS Med Chem Lett, 4, pp.1193~1197 (2013)
- Rzasa RM, "Structure-activity relationships of 3, 4-dihydro-1Hquinazolin-2-one derivatives as potential CDK5 inhibitors", Bioorg Med Chem, 15, pp.6574~6595 (2007)
- pyrimidine-based Pim inhibitors : a template-based approach, "Bioorg Med Chem Lett", 2013, 6178~6182